More on GILD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $91.65 |
|
|||
| Open | $92.01 | ||||
| 52 Wk High | $108.63 | ||||
| 52 Wk Low | $71.39 | ||||
| Day High | $92.80 | ||||
| Day Low | $91.69 | ||||
| P/E | 50.74 | ||||
| EPS | $1.81 | ||||
| Volume | 6,862,234 | ||||
- Form 4 GILEAD SCIENCES, INC. For: Jan 15 Filed by: Dickinson Andrew D
- Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
- Gilead Sciences, US government settle patent case over HIV prevention drugs
- RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
- Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
- Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
- Morgan Stanley upgrades Gilead on HIV treatment growth
- Morgan Stanley Upgrades Gilead Sciences (GILD) to Overweight
- Gilead Sciences (GILD) PT Lowered to $83 as RBC Capital Highlights Biktarvy's Strong Profile
- Form 4 GILEAD SCIENCES, INC. For: Jan 02 Filed by: Berger Dietmar
Entities mentioned with GILD
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Options | View Related Stories »
- JPMorgan | View Related Stories »
- Dividend | View Related Stories »
- Citi | View Related Stories »
- Show More...
